Piramal Pharma Solutions has begun production of initial batches of APIs in new reactor suites at its facility in Riverview, Michigan. This, the company said, represent the first in a three-step process for the development and manufacturing of Phase II clinical trial materials. As part of the programme, technicians are scaling up material from 10-15 kg to 75-80 kg.
UK-based CDMO Sterling Pharma Solutions has completed the acquisition of Novartis’ API facility in Ringaskiddy, near Cork, Ireland. The deal includes an on-going supply agreement to make APIs for cardiovascular, immunology and oncology medicines for Novartis. No financial details were disclosed.
Siegfried has held a groundbreaking ceremony for the largest construction project in its history. The Swiss CDMO will be investing up to CHF 100 million on a large-scale production facility at Minden, Germany. This will have up to 100 m3 of additional reactor capacity for API production when it is commissioned in 2024.
SK Pharmteco has announced a two-phase, $35 million investment to boost both capacity and capabilities at its SK Biotek subsidiary’s manufacturing plant at Swords, Dublin. This is due online in 2024, the campus’s 60th anniversary as a small molecule API manufacture, and will lead to a 50% total increase in capacity.
CDMO Onyx Scientific has opened a second facility at its headquarters site in Sunderland, UK.This doubles its footprint and allows for expansion of all CMC activities, including additional GMP facilities that increases capacity for GMP and commercial API manufacturing capacity by 50%.
Bachem has entered a strategic collaboration under which it will provide the infrastructure and expertise to implement Eli Lilly & Company’s novel manufacturing technology for oligonucleotide APIs. It will also supply R&D and production at its site in Bubendorf, Switzerland, to make GMP-grade material using this technology.
Sumitomo Chemical has announced plans to build a new plant for APIs and intermediates to come onstream in September 2024 at its Oita works on the southern tip of Honshu. This comes in response to growing demand from the small molecule sector. No financial details were given.
Oita, the company said, “can manufacture a wide variety of APIs and intermediates that require complex chemical reactions and also flexibly scale from development to commercialisation”. It is also compliant with EU, US and Japanese GMP standards.
